Eli Lilly’s stock falls

Eli Lilly stock down on Q4 guidance miss
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and global expansion of sales of its diabetes and weight loss drugs should all add up to strong, 32% sales growth in the new year. The company forecasts 2025 sales of $58 billion to $61 billion.
Here’s why Eli Lilly stock is crashing
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello
Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 with $61B Revenue Potential
Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly ( NYSE:LLY) ...
Hosted on MSN49m
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...
Pharmaceutical Technology6h
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Eli Lilly Q4 miss brings buying opportunity, says JPMorgan
JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
bovnews23h
Eli Lilly’s (LLY) Q4 Earnings Fall Short: What’s Next for the Pharma Giant?
Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...
Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating
Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...
Eli Lilly: BofA says buy the dip after shares slide on Q4 miss
BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.
Stocktwits on MSN4h
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...